CoChat

MicroRNA Signatures as Diagnostic and Therapeutic Targets

Waldman, Scott A, Terzic, Andre · 2008 · Clinical Chemistry
Cited by 50

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

MicroRNAs (miRNAs)1 are short, noncoding RNA molecules capable of regulating gene expression at transcription and translation levels(1). Conserved throughout evolution, miRNAs participate in fundamental biologic processes including cell cycle, differentiation, development, metabolism, patterning, and aging. The human genome contains approximately 1000 miRNAs that are estimated to regulate a third of all genes. These regulatory molecules originate, by transcription of distinct genes in the noncoding portions of chromosomes, as precursor RNA molecules containing hundreds to thousands of nucleotides, which undergo distinct nuclear and cytoplasmic processing. Specifically, miRNAs originate in the nucleus as pri-miRNAs, precursors transcribed by RNA polymerase II (Fig. 1 ). Subsequently, cleavage by a ribonuclease III called Drosha and the double-stranded DNA binding protein DGCR8/Pasha generates a hairpin-shaped premiRNA. These intermediates are transported by the nuclear export factor exportin 5/Ran GTP into the cytosol, where they are processed into 19- to 25-nucleotide miRNA duplexes by the ribonuclease III Dicer, in association with the transactivation-responsive RNA-binding protein. These duplexes incorporate as the targeting core of RNA-induced silencing complexes, inducing translational inhibition by cleavage and degradation of messenger RNA or by blocking translation, thereby defining the pool of available genes(1). In this way, miRNAs represent an increasingly recognized component in the multidimensional complexity characterizing information processing at the interface of nucleus and cytoplasm. Importantly, their function has provided novel insight into the integrated genetic circuitry specifying cell fate. Biogenesis of microRNA and microRNA-mediated gene regulation in animal cells. Reprinted with permission(6). © 2005 Massachusetts Medical Society. All rights reserved. Commonly, miRNAs are located in cancer-associated genomic regions, including minimal regions of amplification, loss of heterozygosity, fragile sites, and common breakpoint regions in or near oncogenes or tumor suppressor genes(1). There is increased evidence in human tumors of abnormal expression of miRNAs that have been assigned oncogenic and/or tumor suppressor functions. Although some miRNAs commonly exhibit altered expression across tumors, more often different tumor types express unique patterns of miRNAs, referable to their tissues of origin. In fact, patterns of miRNA expression appear to be a richer source of pathognomonic tumor information than messenger RNA expression profiling. The role of miRNAs in tumorigenesis underscores their value as mechanism-based therapeutic targets in cancer. Similarly, unique patterns of altered microRNA expression provide complex fingerprints that may serve as molecular biomarkers for tumor diagnosis, prognosis of disease-specific outcome, and prediction of therapeutic response(2). The potential value of miRNAs as prognostic and predictive biomarkers in cancer is elegantly highlighted in the recent work of Schetter et al.(3), who compared miRNA expression patterns in colon adenocarcinoma and adjacent normal tissue using a test set and validation cohorts. Specific miRNA signatures distinguished colon cancer from normal colon, and a subset of miRNAs was further demonstrated to exhibit prognostic value. In particular, one specific species of miRNA, miR-21, was expressed in 87% of patients with colon cancer and was revealed as an independent prognostic marker of poor survival(3). In addition, high miR-21 expression predicted worse survival in treated colon cancer patients and poor responsiveness to adjuvant chemotherapy. Beyond prognosis and prediction, miRNAs associated with neoplastic transformation may mediate pathophysiological mechanisms underlying tumorigenesis. Indeed, miR-21 may play a role in tumor growth, invasion, and metastasis by targeting multiple tumor/metastasis suppressor genes(4). These studies of miRNA profiles in colon adenocarcinoma reinforce the utility of these biomarkers in defining the molecular taxonomy of tumors. Similarly, they highlight the potential of miRNA profiling for defining prognosis, stratifying risk, and identifying low- and high-risk populations of patients with cancer. Moreover, they underscore the potential value of miRNAs as mechanism-based therapeutic targets in cancer, an unmet need in the management of colon cancer, the second leading cause of cancer-related mortality(1)(2)(3). The utility of miRNAs as prognostic and predictive markers accentuates the future practice of medicine, reflecting the beginning of the continuum integrating discovery, development, regulatory review, and evidence basis of medicine required to translate advanced technology into clinical practice(5). Whereas marker discovery has driven biomedical innovation, systematic validation to define performance metrics, including reproducibility, sensitivity, and precision, is required for br

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2008.105353

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 50

Metadata

Authors
Waldman, S. A., & Terzic, A.
Venue
Clinical Chemistry
Published
2008-06-01
Volume
54
Issue
6
Pages
943-944
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2106620148
Cited by
50
References
1
FWCI
2.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MicroRNA Signatures as Diagnostic and Therapeutic Targets. https://app.cochat.ai/papers/10.1373/clinchem.2008.105353
The paper
Waldman, S. A., & Terzic, A. (2008). MicroRNA Signatures as Diagnostic and Therapeutic Targets. Clinical Chemistry. https://doi.org/10.1373/clinchem.2008.105353

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.